AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$KOD

BAKER BROS. ADVISORS LP (BAKER FELIX, BAKER JULIAN) purchased $24.3M of KOD (indirect holdings)

BAKER BROS. ADVISORS LP purchased 247,090 indirectly-held shares of Kodiak Sciences Inc. (KOD) at $98.51 ($24.34M total) across 4 trades over 2026-11-04 to 2026-11-05. Filed jointly with 667, L.P. (Director), Baker Bros. Advisors (GP) LLC (Director), Baker Brothers Life Sciences LP (Director), BAKER FELIX (Director) and BAKER JULIAN (Director).

Original reporting
SEC EDGAR · BAKER BROS. ADVISORS LP, 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN
Published Nov 6, 2026, 9:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 10:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$KOD
Bullish
high confidence
Mentioned
$KOD
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KODBullishMed
01

Why it matters

The $24.3M purchase represents a material stake increase for a micro‑cap biotech, likely influencing short‑term price dynamics.

02

Market read

Insider buying by a major shareholder can trigger short‑term buying interest in KOD.

03

What to watch

Potential upcoming clinical trial results or financing events that may offset the positive signal from the purchase.

Relevance 8/10Novelty 7/10Timing: after-hours filing on 2026-11-06

Background

Form 4 filing from SEC EDGAR discloses a director's open‑market purchase of Kodiak Sciences stock.

Company-level read

Ticker impact

$KODBullishHigh confidence
Context

Director and 10% owner purchased 247,090 shares for $24.3M, increasing holdings to over 20M shares.

Expected impact

likely upward pressure as the market prices in the insider purchase

Evidence & confidence

The purchase size ($24M) is material for a micro‑cap biotech and the insider holds a 10% stake, indicating strong confidence.

Market effects

Sector

May boost sentiment in the biotech sector as insider confidence can be seen as a positive signal.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Minimal global impact beyond niche biotech investors.

Counterpoint

What could challenge this read

Insider buying could be a defensive move to support share price ahead of upcoming dilution or negative trial data.

Key entities

  • company
    Kodiak Sciences Inc.

    Biotech company developing therapies for liver diseases.

  • entity
    Baker Bros. Advisors LP

    Investment advisor acting as director and 10% owner of Kodiak Sciences.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

KOD insider trading history →

Related articles

$KODHighAI 8/10

KOD Stock Explodes As Zenkuda Trial Data Rewire Wall Street

Kodiak Sciences Inc (KOD) stock rose 7.91% on October 19, 2026, following positive trial data for its eye drug Zenkuda. The company reported successful Phase 3 DAYBREAK trial results, with analysts raising price targets. KOD has no revenue but has cash and working capital for operations. The stock has seen significant volatility, with some analysts remaining neutral due to valuation concerns.

timothysykes.com
$KODHighAI 9/10

KOD Stock Soars As Zenkuda Trial Fuel Sparks Massive Re‑Rating

Kodiak Sciences Inc (KOD) surged 8.56% after positive Phase 3 trial results for Zenkuda and tabirafusp-ted, showing non-inferior vision gains to aflibercept. Analysts raised price targets, with LifeSci Capital at $145 and Jefferies at $112. KOD has $132.1M in cash, negative operating cash flow, and a current ratio of 2.5.

stockstotrade.com
$KODMed

KOD Stock Rockets As DAYBREAK Trial Rewrites Biotech Expectations

Kodiak Sciences Inc (KOD) rose 8.56% on October 15, 2026, following positive Phase 3 DAYBREAK trial results for its treatments Zenkuda and tabirafusp-ted. The trial met primary endpoints, showing vision gains and favorable safety. Analysts raised price targets, with LifeSci Capital setting it at $145. KOD's stock surged over 100% on September 28, 2026, after the trial news. The company remains pre-revenue but has a strong cash position.

timothysykes.com
$KODHighAI 8/10

Kodiak Sciences Tumbles Despite Strong Phase 3 Trial

Kodiak Sciences (KOD) shares fell 7.84% despite positive Phase 3 trial results, as investors took profits and raised concerns about competition and commercial infrastructure. The company's long-term prospects remain uncertain due to cash burn and funding needs, despite strong clinical data. KOD has a market cap of $6.24B and is up 255.01% YTD.

tipranks.com
$KODHighAI 8/10

H.C. Wainwright raises Kodiak Sciences stock price target on trial data

H.C. Wainwright raised its price target on Kodiak Sciences (NASDAQ:KOD) to $126 from $96, maintaining a Buy rating. The move follows positive Phase 3 DAYBREAK trial results for Zenkuda and Tabirafusp in wet age-related macular degeneration. The trial met its primary endpoint, with Zenkuda showing sustained efficacy. Kodiak plans to submit a Biologics License Application in Q4 2026. The stock is up 741% over the past year, trading at $99.87. Other analysts have mixed outlooks on the company.

investing.com